Suppr超能文献

亲环蛋白抑制剂Debio-025在丙型肝炎和人类免疫缺陷病毒合并感染患者中显示出强效的抗丙型肝炎作用。

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

作者信息

Flisiak Robert, Horban Andrzej, Gallay Philippe, Bobardt Michael, Selvarajah Suganya, Wiercinska-Drapalo Alicja, Siwak Ewa, Cielniak Iwona, Higersberger Jozef, Kierkus Jarek, Aeschlimann Christian, Grosgurin Pierre, Nicolas-Métral Valérie, Dumont Jean-Maurice, Porchet Hervé, Crabbé Raf, Scalfaro Pietro

机构信息

Department of Infectious Diseases, Medical University of Bialystok, Bialystok, Poland.

出版信息

Hepatology. 2008 Mar;47(3):817-26. doi: 10.1002/hep.22131.

Abstract

UNLABELLED

Debio-025 is an oral cyclophilin (Cyp) inhibitor with potent anti-hepatitis C virus activity in vitro. Its effect on viral load as well as its influence on intracellular Cyp levels was investigated in a randomized, double-blind, placebo-controlled study. Mean hepatitis C viral load decreased significantly by 3.6 log(10) after a 14-day oral treatment with 1200 mg twice daily (P < 0.0001) with an effect against the 3 genotypes (1, 3, and 4) represented in the study. In addition, the absence of viral rebound during treatment indicates that Debio-025 has a high barrier for the selection of resistance. In Debio-025-treated patients, cyclophilin B (CypB) levels in peripheral blood mononuclear cells decreased from 67 +/- 6 (standard error) ng/mg protein (baseline) to 5 +/- 1 ng/mg protein at day 15 (P < 0.01).

CONCLUSION

Debio-025 induced a strong drop in CypB levels, coinciding with the decrease in hepatitis C viral load. These are the first preliminary human data supporting the hypothesis that CypB may play an important role in hepatitis C virus replication and that Cyp inhibition is a valid target for the development of anti-hepatitis C drugs.

摘要

未标记

Debio-025是一种口服亲环素(Cyp)抑制剂,在体外具有强大的抗丙型肝炎病毒活性。在一项随机、双盲、安慰剂对照研究中,研究了其对病毒载量的影响以及对细胞内Cyp水平的影响。每日两次口服1200毫克,经过14天治疗后,丙型肝炎病毒平均载量显著下降3.6 log(10)(P < 0.0001),对研究中所代表的3种基因型(1、3和4)均有作用。此外,治疗期间无病毒反弹表明Debio-025对耐药性的选择具有高屏障。在接受Debio-025治疗的患者中,外周血单核细胞中环孢菌素B(CypB)水平从67±6(标准误)纳克/毫克蛋白质(基线)在第15天降至5±1纳克/毫克蛋白质(P < 0.01)。

结论

Debio-025导致CypB水平大幅下降,这与丙型肝炎病毒载量的降低相一致。这些是支持CypB可能在丙型肝炎病毒复制中起重要作用以及Cyp抑制是抗丙型肝炎药物开发的有效靶点这一假说的首批初步人体数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验